MedTrace Logo

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study)

NCT06628921 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-01-21

No results posted yet for this study

Summary

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.

The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe\_5)

Conditions

Interventions

DRUG

Eptinezumab 100 or 300 mg ev

Eptinezumab administered for migraine prevention in patients but with ongoing migraine attacks.

Sponsors & Collaborators

  • Società Italiana per lo Studio delle Cefalee

    collaborator OTHER

  • Fondazione Policlinico Universitario Campus Bio-Medico

    collaborator OTHER

  • SISC RICe Group

    collaborator UNKNOWN

  • University of Florence

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-30
Primary Completion
2026-10-30
Completion
2026-10-30
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06628921 on ClinicalTrials.gov